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Discriminating Between Cardiac and Pulmonary
Dysfunction in the General Population With Dyspnea
by Plasma Pro-B-Type Natriuretic Peptide
Rasmus Mogelvang, MD,*† Jens P. Goetze, MD, DMSC,*‡ Peter Schnohr, MD, DMSC,*
Peter Lange, MD, DMSC,*§ Peter Sogaard, MD, DMSC,† Jens F. Rehfeld, MD, DMSC,‡
Jan S. Jensen, MD, PHD, DMSC*†
Copenhagen, Denmark
Objectives This study was designed to determine whether measurement of plasma pro-B-type natriuretic peptide (proBNP)
could be used in discriminating between cardiac and pulmonary dyspnea in the general population.
Background Natriuretic peptides are useful markers in ruling out acute cardiac dyspnea in the emergency department, but
their diagnostic significance in evaluating chronic dyspnea in the general population is unknown.
Methods Within the Copenhagen City Heart Study, a large, community-based population study, dyspnea was evaluated by
spirometry, oxygen saturation, echocardiography, and plasma proBNP.
Results Of 2,929 participants, 959 reported dyspnea. The plasma proBNP concentration was higher in the group with
dyspnea (mean 17.8 pmol/l; 95% confidence interval [CI] 16.3 to 19.4 pmol/l) than in the group without (10.6
pmol/l; 95% CI 10.0 to 11.4 pmol/l; p  0.001). In the group with dyspnea, left ventricular hypertrophy and/or
systolic dysfunction was associated with a 2.6-fold increase in plasma proBNP concentration (p  0.001),
whereas pulmonary dysfunction was not associated with increased plasma proBNP (p  0.66). Using multivari-
able regression analysis, a model to estimate the expected concentration of plasma proBNP based on age and
gender was established for dyspneic subjects: an actual plasma proBNP concentration below half of the ex-
pected value ruled out left ventricular systolic and diastolic dysfunction (sensitivity 100%, 95% CI 100% to
100%; specificity 15%, 95% CI 12% to 17%).
Conclusions In the general population with dyspnea, plasma proBNP concentrations are increased in left ventricular dilata-
tion, hypertrophy, systolic dysfunction, or diastolic dysfunction, but are unaffected by pulmonary
dysfunction. (J Am Coll Cardiol 2007;50:1694–701) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.07.073r
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pyspnea is a common symptom in patients seeking
edical care. Cardiac and pulmonary disorders are 2
ommon causes of dyspnea, and the clinical distinction
etween the 2 can be very difficult (1,2). These conditions
ften have an adverse and potentially hazardous treat-
ent, emphasizing the need for a correct diagnosis. In
ospital settings, echocardiography is often used when
etecting structural cardiac abnormalities, but it is not
eadily accessible in the general practice. In addition, to
rom the *Copenhagen City Heart Study, Epidemiological Research Unit, Bispebjerg
ospital, †Department of Cardiology, Gentofte Hospital, ‡Department of Clinical
iochemistry, Rigshospitalet, and §Department of Heart and Lung Diseases,
vidovre Hospital, University of Copenhagen, Copenhagen, Denmark. This study
as supported by grants from the Lundbeck Foundation, the Novo Nordisk
oundation, Builder L.P. Christensen and Wife’s Foundation, Raimond and Dagmar
inggaard-Bohn’s Foundation, and Bank Manager Hans Stener and Wife’s Foun-
ation, Copenhagen, Denmark.p
Manuscript received May 14, 2007; revised manuscript received July 5, 2007,
ccepted July 23, 2007.efer every patient with dyspnea in the general population
o echocardiographic examination demands considerable
esources. An assessable biomarker that can discriminate
ulmonary from cardiac disorders would therefore be
seful.
See page 1702
The recognition of natriuretic peptides secreted from the
verloaded heart has been the basis for a key study by Davis
t al. (3) and subsequent studies (4–8) that assessed the
iagnostic value of measuring natriuretic peptides to differ-
ntiate between acute pulmonary and cardiac dyspnea. The
oncept that measurement of the peptides is useful (3–8)
nd cost effective (9) in the emergency department is now
ell documented. However, the data are limited to selected
atients and cannot be extrapolated to the general
opulation.
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October 23, 2007:1694–701 Discriminating Cardiac From Pulmonary DyspneaIf the natriuretic peptides are true markers of cardiac and
ot pulmonary disorder, they might have a place not only in
he evaluation of the acutely ill but also in ambulatory
ettings.
We therefore performed a large population-based study
valuating the association between the concentration of plasma
ro-B-type natriuretic peptide (proBNP) and dyspnea as
haracterized by spirometry, oxygen saturation, and
chocardiography.
ethods
tudy population. This study was performed as a substudy
f the Fourth Copenhagen City Heart Study, a longitudinal
ohort study of cardiovascular disease and risk factors
10,11). At the first examination in 1976 to 1978, a random
ample of 19,329 predominantly white citizens living within
well-defined area of the inner Copenhagen City boundary
as drawn from the Central Office of Civil Registration and
nvited to take part in the study. The sample was stratified
y gender and age (5-year age strata from the age of 20
ears) so that nearly equal numbers within each stratum
ere invited. At the fourth examination in 2001 to 2003, a
otal of 12,600 people were invited in a random order. This
tudy population consisted of participants from the previous
xaminations (n  11,600), supplemented by a random
ample of people from the younger age strata (n  1,000).
f the 12,600 people, 6,238 (49.5%) participated, and 2,929
47.0%) randomly selected men and women (20 to 95 years)
nderwent both an echocardiographic and a spirometric
xamination, thus constituting the population included in
he present report. Whether or not a participant underwent
chocardiography and spirometry was completely indepen-
ent of his or her health status and other risk factors.
All subjects gave informed consent to participate, and the
tudy was performed in accordance with the Second Helsinki
eclaration and approved by the regional ethics committee.
ealth examination. Hypertension was defined as systolic
lood pressure 140 mm Hg, diastolic blood pressure 90
m Hg, or use of antihypertensive medication (12). Ischemic
eart disease was defined as either a history of hospital
dmission because of acute coronary artery occlusion, percuta-
eous coronary intervention, or coronary artery bypass grafting,
r major ischemic alterations on the electrocardiogram as
efined by the Minnesota codes 1.1-3. Diabetes mellitus was
efined as plasma glucose concentration11.1 mmol/l, use of
nsulin or other antidiabetic medicine, self-reported disease, or
emoglobin A1c level 7.0% (13,14).
A slightly modified Medical Research Council (MRC)
yspnea scale was used for the assessment of dyspnea:
ategory 0, no dyspnea; category 1, troubled by shortness of
reath when hurrying on level ground or walking up a low
ill; category 2, walks slower than people of the same age on
evel ground because of breathlessness; category 3, must stop
ecause of breathlessness when walking at own pace on level
round; category 4, breathless when dressing or undressing; Mnd category 5, breathless at rest
r when sitting still. Dyspnea of
RC categories 1 and 2 was
onsidered mild and of categories
, 4, and 5 was considered severe.
lasma proBNP measurement.
he plasma proBNP concentra-
ion was quantified using a
rocessing-independent assay
Fig. 1) (15). The analytical vali-
ation of this assay has been re-
orted elsewhere (16,17). The
rocessing-independent assay re-
ults are fully comparable to the
ommercially available Modular
-terminal-proBNP assay by
oche (Karlsruhe, Germany) on
inear regression analysis (r2 
.91; slope 1.37 0.02; p 0.001) with an average 1.7-fold
ifference (mean plasma proBNP 222 pmol/l, 95% confi-
ence interval [CI] 201 to 243 pmol/l vs. mean N-terminal-
roBNP 386 pmol/l, 95% CI 328 to 442 pmol/l).
ulmonary function. Forced expiratory volume in 1 sec
FEV1) and forced vital capacity (FVC) were measured with a
ry wedge spirometer (Vitalograph, Maidenhead, United
ingdom) which was calibrated daily with a 1-l syringe. At
ach examination, 3 sets of values were obtained, and as a
riterion for correct performance of the procedure at least 2
easurements differing by 5% had to be produced. The
ighest measurement of FEV1 and FVC was used in the
nalyses as absolute values and as percentage of predicted values
sing internally derived reference values based on a sub sample
f healthy never-smokers. Resting peripheral oxygen saturation
as measured by pulse oxymetry. Subjects were considered as
aving pulmonary dysfunction if FEV1 or FVC were below
0% of the predicted value, the oxygen saturation was below
2%, or a history of asthma was reported.
chocardiography. Three experienced echocardiography
echnicians using a GE Vingmed Ultrasound’s Vivid Five
ith a 2.5-MHz probe (Horten, Norway) performed all
chocardiograms. The collected data were stored on
agneto-optical discs and an external FireWire hard drive
LaCie, France), and analyzed off-line by 1 expert with the
choPAC software version 6.4.3f1 (GE Medical, Horten,
orway). All subjects were examined with 2-dimensional
nd M-mode echocardiography in the left lateral decubitus
osition. All images were recorded in second harmonic
maging at the time of end-expiration. One loop of the
pical 4-chamber, 2-chamber, and long-axis projections was
ecorded, more if atrial fibrillation was present. The 16
tandard segments model, as suggested by the American
ociety of Echocardiography (18), was used for evaluation
f regional function. Left ventricular systolic dysfunction
as defined as left ventricular ejection fraction 50%.
One loop of the parasternal long axis was recorded and 1
Abbreviations
and Acronyms
CI  confidence interval
FEV1  forced expiratory
volume in 1 s
FVC  forced vital capacity
MRC  Medical Research
Council
NPV  negative predictive
value
PPV  positive predictive
value
ProBNP  pro-B-type
natriuretic peptide
ROC  receiver-operator
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Discriminating Cardiac From Pulmonary Dyspnea October 23, 2007:1694–701f the mitral leaflets and the tips of the papillary muscles. If
he correct angle could not be obtained, 2-dimensional
mages were used instead to quantify the myocardial thick-
ess and the dimensions of the left ventricle. Left ventric-
lar mass index was calculated as the anatomic mass (19)
ivided by body surface area (20). Left ventricular hyper-
rophy was defined as left ventricular mass index104 g/m2
or women and 116 g/m2 for men (21). Left ventricular
ilatation was considered if the diameter of the left ventricle
t end-diastole/height 3 cm/m.
Pulsed-wave Doppler at the apical position was used to
ecord mitral inflow (between mitral leaflets) and left
entricular outflow. Peak velocities of early (E) and atrial
A) diastolic filling and deceleration time of the E-wave
DT) were measured and the E/A ratio was calculated.
evere diastolic dysfunction was defined as DT 140 ms
nd E/A50 years 2.5, E/A50–70 years 2, or E/A70 years
1.5, respectively. The time interval from mitral valve
losing to opening (TST) was determined as the period
rom the end to the onset of the mitral inflow, left
entricular ejection time (ET) was determined as the period
rom onset to the end of the left ventricular outflow, and the
yocardial performance index was calculated as: (TST 
T)/ET (22). Myocardial performance was considered
educed if the myocardial performance index was 0.40.
tatistical analyses. The plasma proBNP concentrations
n the population were positively skewed and therefore
ogarithmically transformed before further statistical analy-
is (unless stated otherwise): the mean values presented in
he text refer to geometric mean values. Comparisons
etween groups were performed by the Student t test and
Figure 1 Differences in Measurement of proBNP Between the P
(A) Summary of the processing-independent assay (PIA) for measurement of pro-B
cleaved with an endoprotease (trypsin) releasing an N-terminal fragment (proBNP 1
proBNP. Note that both proBNP 1-108 and 1-76 will be quantified with equal affini
Roche (Karlsruhe, Germany). Two antibodies raised against distinct regions in proB
lated region in endogenous proBNP. The assay is calibrated with synthetic, nonglyisher exact test. Linearity between plasma proBNP values Ind continuous variables was examined visually by scatter
lots. According to these, plasma proBNP was linearly
orrelated to the square of age. The ability of plasma
roBNP to detect cardiac dysfunction was assessed using
eceiver-operating characteristics (ROC). Associations to
lasma proBNP were tested by univariate and multivariable
egression analyses for the echocardiographic (left ventric-
lar systolic dysfunction, hypertrophy, dilatation, diastolic
ysfunction, myocardial performance index) and the non-
chocardiographic (age, gender, body mass index, plasma
reatinine, diabetes, hypertension, ischemic heart disease,
ulmonary dysfunction) parameters. These parameters were
hosen because they have been shown to influence the
lasma concentrations of natriuretic peptides. To establish a
arsimonious model for predicting plasma proBNP concen-
rations, the most insignificant parameter in the multivari-
ble analysis was removed by backward elimination (reten-
ion threshold, p 0.05). Forward selection was undertaken
fterward, yielding the same result. Linearity, variance
omogeneity, and the assumption of normality were tested
ith plots of residuals. Interaction was tested among the
ignificant parameters. The diagnostic performances of
ifferent ratios of measured (untransformed) to predicted
lasma proBNP in detecting left ventricular systolic dys-
unction and/or diastolic dysfunction were then evaluated.
he 95% CIs for the diagnostic estimates were calculated
sing bootstrap estimation (10,000 replications) with the
.5th and 97.5th percentiles as lower and upper limits,
espectively. Values of p  5% on 2-sided tests were
onsidered significant. All analyses were performed by SAS
oftware (SAS System for Windows, release 8.02, SAS
ssing-Independent Assay and the Roche Assay
atriuretic peptide (proBNP) 1-108 and 1-76. During analysis, both peptides are
ed boxes). The larger, blue boxes represent the glycosylated midregion in
irrespective of the glycosylation degree. (B) The N-terminal (NT)-proBNP assay by
76 are used in a sandwich assay. One antibody is raised against the glycosy-
ted proBNP 1-76, and the assay affinity to proBNP 1-108 is unknown.roce
-type n
-21, r
ty and
NP 1-
cosylanstitute Inc., Cary, North Carolina).
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October 23, 2007:1694–701 Discriminating Cardiac From Pulmonary Dyspneaesults
he characteristics of the study population are listed in
able 1. The 2 groups differed significantly with regard to
lmost all of the shown characteristics, reflecting a higher
ickness profile in the dyspneic group (Table 1). Plasma
roBNP is eliminated by the kidneys, but there was no
ignificant difference between the groups regarding plasma
reatinine. Almost one-half of the dyspneic subjects had
either an abnormal echocardiogram nor pulmonary dys-
unction (Fig. 2). Not only was the mean plasma proBNP
oncentration higher in the group with dyspnea than in the
roup without, but also the plasma proBNP concentrations
ncreased according to the severity of dyspnea (Fig. 3), even
fter adjustment for age and gender.
Plasma proBNP concentration is increased in individuals
ith left ventricular systolic dysfunction and/or hypertrophy
23). To evaluate the effect of pulmonary and cardiac
ysfunction on plasma proBNP, the dyspneic population
as divided into 4 strata according to cardiac and pulmo-
ary dysfunction. As shown in Figure 4, the mean plasma
roBNP concentration was greatly increased in the groups
ith cardiac dysfunction (left ventricular systolic dysfunc-
ion and/or hypertrophy), whereas it was unaffected by
opulation Demographic
Table 1 Population Demographic
No Dyspnea (n 
Male gender, % 45.8 (43.6–4
Age, yrs 54.4 (53.6–5
Body mass index, kg/m2 24.8 (24.6–2
Creatinine, mol/l 79.5 (78.9–8
proBNP, pmol/l 10.6 (10.0–1
Hypertension, % 37.4 (35.3–3
Diabetes, % 6.6 (5.5–7.
Ischemic heart disease, % 4.7 (3.8–5.
Myocardial performance index 0.40, % 44.0 (41.5–4
Left ventricular hypertrophy, % 11.0 (9.6–12
Left ventricular dilation, % 23.8 (21.9–2
Severe diastolic dysfunction, % 0.9 (0.4–1.
Left ventricular ejection fraction 50%, % 0.5 (0.2–0.
Pulmonary dysfunction, % 5.3 (4.3–6.
he 95% confidence intervals are given in parentheses.
proBNP  pro-B-type natriuretic peptide.Figure 2 Flow Diagram of the Study Populationulmonary status. Overall, the mean plasma proBNP was
.6-fold higher in subjects with cardiac dysfunction com-
ared with subjects without (38.0 pmol/l, 95% CI 32.0 to
5.2 pmol/l vs. 14.9 pmol/l, 95% CI 13.5 to 16.4 pmol/l, p
0.001). In contrast, there was no significant difference
etween the group with pulmonary dysfunction and the
roup without (18.6 pmol/l, 95% CI 15.2 to 22.7 pmol/l vs.
7.6 pmol/l, 95% CI 16.0 to 19.4 pmol/l, p  0.66).
otably, these differences persisted after adjusting for age,
ender, diabetes, hypertension, and ischemic heart disease,
or both cardiac (p  0.001) and pulmonary dysfunction (p
0.85). There was no interaction between cardiac and
ulmonary dysfunction on plasma proBNP concentrations
p  0.19).
0) Dyspnea (n  959) p Value
32.7 (29.8–35.6) p  0.001
62.6 (61.7–63.7) p  0.001
26.7 (26.4–27.0) p  0.001
80.2 (79.1–81.2) p  0.29
17.8 (16.3–19.4) p  0.001
53.7 (50.6–56.9) p  0.001
12.3 (10.2–14.4) p  0.001
15.2 (12.9–17.5) p  0.001
50.7 (46.9–54.4) p  0.001
17.7 (15.3–20.2) p  0.001
31.5 (28.5–34.4) p  0.001
1.5 (0.7–2.3) p  0.13
2.7 (1.7–3.8) p  0.001
18.0 (15.6–20.5) p  0.001
Figure 3 Mean Plasma proBNP Concentrations
According to Severity of Dyspnea
Dyspnea was classified according to a slightly modified Medical Research
Council (MRC) dyspnea scale. No dyspnea refers to MRC category 0, mild dys-
pnea to MRC category 1 to 2, and severe dyspnea to MRC category 3 to 5.
proBNP  pro-B-type natriuretic peptide.1,97
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Discriminating Cardiac From Pulmonary Dyspnea October 23, 2007:1694–701The area under the ROC curve was 0.73 (95% CI 0.70 to
.76) for detecting cardiac dysfunction, whereas it was 0.72
95% CI 0.68 to 0.76) and 0.75 (95% CI 0.68 to 0.82) for
etecting left ventricular hypertrophy and systolic dysfunc-
ion, respectively.
To assess whether parameters other than left ventricular
ystolic dysfunction and hypertrophy were associated with
lasma proBNP in subjects with dyspnea, univariate and
ultivariable regression analyses were performed for several
arameters; the results are shown in Table 2, displaying the
ignificant parameters after backward elimination for pre-
icting plasma proBNP in the general population with
yspnea. Left ventricular systolic dysfunction and diastolic
ysfunction both imposed a considerable effect on the
lasma proBNP concentration by increasing it more than
-fold, whereas the effects of left ventricular hypertrophy
nd left ventricular dilatation were only moderate. Interest-
ngly, plasma proBNP concentrations increased exponen-
ially with age (Table 2). Univariate analysis showed that a
igh myocardial performance index was significantly asso-
iated with increased plasma proBNP concentration both as
continuous (p  0.01) and as a dichotomous variable
myocardial performance index 0.40 or 0.40; p  0.01),
hich persisted after adjusting for age and gender. How-
ver, this effect was insignificant when left ventricular
ystolic dysfunction, diastolic dysfunction, or hypertrophy
as included in the analysis.
Although body mass index, hypertension, diabetes, isch-
mic heart disease, and plasma creatinine were significant in
he univariate analyses, the effects of all of these parameters
ere insignificant when combined with age, gender, and the
chocardiographic parameters. Thus, body mass index 25
g/m2 (p  0.79), diabetes (p  0.60), hypertension (p 
.54), ischemic heart disease (p  0.18), plasma creatinine
120 mol/l (p  0.40), and pulmonary dysfunction (p 
Figure 4 Mean Plasma proBNP According to Pulmonary and
Cardiac Dysfunction in Dyspneic Subjects (n  959)
Bars indicate standard errors. proBNP  pro-B-type natriuretic peptide..81) were all insignificant and, therefore, were eliminated
vrom the final model. To assess the association of plasma
roBNP concentrations with plain spirometric measures
FEV1 and FVC), these were subsequently evaluated in the
nal model. Neither FEV1 (p  0.60) nor FVC (p  0.84)
ere associated with plasma proBNP.
The expected level of any dyspneic person’s plasma
roBNP can be calculated from Table 2. Thus, if a person’s
yspnea is caused by left ventricular systolic or diastolic
ysfunction, the plasma proBNP concentration would be
.3 or 2.2 times higher, respectively, than expected from age
nd gender alone (Table 2). If the measured plasma
roBNP is higher than expected from age and gender alone,
he diagnostic performance in detecting left ventricular
ystolic and/or diastolic dysfunction in dyspneic subjects is:
ensitivity 92% (95% CI 82% to 100%), specificity 33%
95% CI 30% to 36%), negative predictive value (NPV) 99%
95% CI 98% to 100%), positive predictive value (PPV) 6%
95% CI 4% to 8%), and accuracy 36% (95% CI 33% to
9%). If the measured plasma proBNP is more than 2.5
imes the expected concentration in relation to age and
ender, then the diagnostic performance in detecting left
entricular systolic and/or diastolic dysfunction in dyspneic
ubjects is: sensitivity 61% (95% CI 44% to 76%), specificity
8% (95% CI 75% to 81%), NPV 98% (95% CI 97% to
9%), PPV 11% (95% CI 7% to 16%), and accuracy 77%
95% CI 74% to 80%). Conversely, if a person’s measured
lasma proBNP level is below one-half of the expected
oncentration, then left ventricular systolic or diastolic
ysfunction can be ruled out (sensitivity 100%, 95% CI
00% to 100%; specificity 15%, 95% CI 12% to 17%; NPV
00%, 95% CI 100% to 100%; PPV 5%, 95% CI 4% to 7%;
nd accuracy 18%, 95% CI 16% to 21%) (Fig. 5).
mpact of Main Parameters on Plasma proBNPoncentration in Population With Dys nea
Table 2 Impact of Main Parameters on Plasma proBNPConcentration in a Population With Dyspnea
20-yr-old dyspneic woman* 6.1 pmol/l
If male gender  0.7 (0.6–0.9) p  0.001
If left ventricular dilatation  1.3 (1.1–1.6) p  0.001
If left ventricular hypertrophy  1.5 (1.2–1.9) p  0.001
If severe diastolic dysfunction  2.2 (1.1–4.1) p  0.02
If left ventricular systolic dysfunction  2.3 (1.3–4.1) p  0.01
If age over 20 yrs  e(age – 20 yrs)
2  
† p  0.001
For example
If age  40 yrs  1.2 (1.2–1.2)
If age  50 yrs  1.5 (1.4–1.6)
If age  60 yrs  2.1 (1.9–2.4)
If age  70 yrs  3.3 (2.7–3.9)
If age  80 yrs  5.5 (4.3–7.1)
If age  90 yrs  10.2 (7.2–14.4)
he 95% confidence intervals are given in parentheses. *The benchmark is a 20-yr-old dyspneic
oman with a plasma proBNP of 6.1 pmol/l. For example, a 60-yr-old dyspneic man has an
xpected plasma proBNP level of 9.0 pmol/l (6.1 pmol/l  0.7  2.1), whereas the expected
lasma proBNP is 20.6 pmol/l (6.1 pmol/l  0.7  2.1  2.3) if the same man has known left
entricular systolic dysfunction. †  0.000473 (0.000402–0.000545).
proBNP  pro-B-type natriuretic peptide.
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October 23, 2007:1694–701 Discriminating Cardiac From Pulmonary Dyspneaiscussion
e examined the diagnostic utility of plasma proBNP
easurement for cardiac and pulmonary dyspnea in a large,
opulation-based study. Dyspnea was evaluated by spirom-
try, oxygen saturation, echocardiography, and plasma
roBNP. We found that pulmonary function, in contrast to
ardiac function, has no influence on plasma proBNP
oncentrations. Furthermore, left ventricular dilatation, hy-
ertrophy, systolic dysfunction, and diastolic dysfunction
ave a considerable impact on plasma proBNP concentra-
ions. We therefore established a model predicting plasma
roBNP concentrations from age, gender, and the echocar-
iographic parameters. Finally, we determined the diagnos-
ic performance of plasma proBNP as a rule-out and rule-in
arker of left ventricular systolic or diastolic dysfunction in
general population with dyspnea.
Not surprisingly, pulmonary and cardiac dysfunctions
ere more common among subjects with dyspnea than
mong those without. Hence, a greater prevalence of isch-
mic heart disease and risk factors (hypertension, diabetes,
besity, age) was observed in the dyspneic group (Table 1).
Subjects with dyspnea had higher plasma proBNP con-
entrations than those without dyspnea. In addition to this,
lasma proBNP increased as a function of MRC classes.
his correlation between natriuretic peptides in circulation
nd the severity of dyspnea in the general population
ompares well with the original finding by Maisel et al. (5)
or patients with acute dyspnea at emergency care facilities.
Myocardial performance index correlated positively with
lasma proBNP concentrations in the univariate analysis,
ut the effect was abolished in the multivariable analysis,
ncluding left ventricular systolic dysfunction, diastolic dys-
unction, and/or hypertrophy. This confirms that myocar-
ial performance index reflects a combination of systolic and
Figure 5 Curves for Expected Level of Plasma proBNP Accordin
A measured pro-B-type natriuretic peptide (proBNP) above the blue area indicates
and/or diastolic dysfunction. A measured proBNP below the blue area indicates a
stolic dysfunction can be ruled out. A measured proBNP in the blue area indicates
ther diagnostic evaluation is required.iastolic function (22). tIn keeping with the vast documentation (24–26), our
ndings sustain that the natriuretic peptides are dependent
n age and gender. Notably, we found that plasma proBNP
oncentrations increase exponentially with age. For exam-
le, a 20-year-old dyspneic man has an expected plasma
roBNP level of 4 pmol/l, compared with 34 pmol/l in an
0-year-old dyspneic woman (Table 2). Hence, age and
ender must be taken into account when establishing
eference intervals for plasma proBNP (Fig. 5).
Distinguishing between cardiac and noncardiac causes of
yspnea is difficult without echocardiography. However, it
s not feasible to refer every single person with dyspnea in
he general population for an echocardiographic examina-
ion. Using plasma proBNP measurement as guidance for
urther examination would ease the diagnostic evaluation of
yspnea in this setting. Several studies have shown that the
se of natriuretic peptides in screening of different popula-
ions can be cost effective (9,27–29). We present a new
odel to calculate the expected concentration of plasma
roBNP for a given person with dyspnea adjusting for age
nd gender. A person with dyspnea and a plasma proBNP
oncentration above the blue area in Figure 5 should be
eferred to echocardiography, whereas a person with a
lasma proBNP below the blue area should be examined for
oncardiac causes of dyspnea, e.g., spirometry. If the plasma
roBNP is in the blue area, there exists only a small risk of
eft ventricular systolic and/or diastolic dysfunction, and
eferral to echocardiography should, in addition to the
lasma proBNP level, depend on the physical examination,
namnesis, electrocardiography, and perhaps chest radio-
raph.
Of 959 participants complaining of dyspnea, 462 (48%)
ad a normal echocardiogram and normal pulmonary func-
ion test. Most of these people (83%) were only complaining
f mild dyspnea. Compared with their nondyspneic coun-
Gender and Age for Dyspneic Subjects
2.5 times the expected level and thus a high risk of left ventricular systolic
less than one-half of the expected level and thus left ventricular systolic and dia-
he risk of left ventricular systolic and/or diastolic dysfunction is small and fur-g to
a value
value
that terparts, they were characterized by higher age, higher body
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moking, and lower level of physical activity.
Conventional echocardiography does not provide much
nformation about longitudinal myocardial contractility, which
s impaired initially in ischemic heart disease. Further research
ith more advanced modalities, e.g., tissue Doppler imaging, is
eeded to determine the myocardial function of dyspneic
ersons with normal conventional echocardiograms.
tudy limitations. Certain limitations of the present study
ust be taken into account: 1) the dichotomization of
ulmonary function is a simplification that may lead to loss
f information because it tends to equalize severe and mild
ases of pulmonary dysfunction. In addition, the chosen
hreshold can be an object for discussion. To compensate for
his, we separately analyzed the influence on plasma
roBNP of FEV1 and FVC as continuous variables (percent
f predicted). Both parameters were insignificant in the
nivariate analysis and in the multivariable regression anal-
ses leading to the final model (Table 2). 2) Although not
valuating right ventricular function, the proportion of
ulmonary hypertension among subjects with pulmonary
ysfunction could not be determined. 3) The lack of
nformation made it impossible to stratify according to the
uration of dyspnea. This implies that participants with
hort-lived or prolonged periods of dyspnea were treated
imilarly in the analyses. On the other hand, when adjusting
or the severity of dyspnea, our results were unchanged. 4)
dentification of cardiac dysfunction using echocardiogra-
hy is different from identifying that cardiac disease is the
rigin of dyspnea. The latter additionally requires detailed
atient history, physical examination, and, at times, addi-
ional tests (e.g., D-dimers and computed tomography
cans). 5) The presented model has not been confirmed by a
alidation sample; although validated statistically using boot-
trapping, future studies are required to confirm the model.
onclusions
he present findings sustain the connotation that the
oncentration of plasma proBNP is increased in the pres-
nce of left ventricular dilatation, hypertrophy, systolic
ysfunction, and/or diastolic dysfunction. The crucial point,
owever, is that plasma proBNP is unaffected by pulmonary
unction. Thus, if pulmonary dysfunction is suspected, then
ulmonary status should be pursued, regardless of plasma
roBNP level. In contrast, if plasma proBNP is higher than
xpected in relation to age and gender, then cardiac dys-
unction is likely and cardiac status should be evaluated
egardless of the pulmonary status.
eprint requests and correspondence: Dr. Rasmus Mogelvang,
epartment of Cardiology, Gentofte Hospital, University of
openhagen, Post 4210, 65 Niels Andersens Vej, DK-2900
ellerup, Denmark. E-mail: Rasmus.Mogelvang@get2net.dk. 2EFERENCES
1. Pratter MR, Curley FJ, Dubois J, Irwin RS. Cause and evaluation of
chronic dyspnea in a pulmonary disease clinic. Arch Intern Med
1989;149:2277–82.
2. Remes J, Miettinen H, Reunanen A, Pyorala K. Validity of clinical
diagnosis of heart failure in primary health care. Eur Heart J 1991;12:
315–21.
3. Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic
peptide in assessment of acute dyspnoea. Lancet 1994;343:440–4.
4. Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P,
Maisel A. Utility of a rapid B-natriuretic peptide assay in differenti-
ating congestive heart failure from lung disease in patients presenting
with dyspnea. J Am Coll Cardiol 2002;39:202–9.
5. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement
of B-type natriuretic peptide in the emergency diagnosis of heart
failure. N Engl J Med 2002;347:161–7.
6. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic
peptide in the evaluation and management of acute dyspnea. N Engl
J Med 2004;350:647–54.
7. Ray P, Arthaud M, Lefort Y, Birolleau S, Beigelman C, Riou B.
Usefulness of B-type natriuretic peptide in elderly patients with acute
dyspnea. Intensive Care Med 2004;30:2230–6.
8. Chen AA, Wood MJ, Krauser DG, et al. NT-proBNP levels,
echocardiographic findings, and outcomes in breathless patients: re-
sults from the ProBNP Investigation of Dyspnoea in the Emergency
Department (PRIDE) echocardiographic substudy. Eur Heart J 2006;
27:839–45.
9. Mueller C, Laule-Kilian K, Schindler C, et al. Cost-effectiveness of
B-type natriuretic peptide testing in patients with acute dyspnea. Arch
Intern Med 2006;166:1081–7.
0. Appleyard M, Hansen AT, Schnohr P, Jensen G, Nyboe J. The
Copenhagen City Heart Study. A book of tables with data from the
first examination (1976-78) and a five-year follow-up (1981-83).
Scand J Soc Med 1989;170:1–160.
1. Schnohr P, Jensen G, Lange P, Scharling H, Appleyard M. The
Copenhagen City Heart Study. Tables with data from the third
examination 1991-94. Eur Heart J 2001;3:1–83.
2. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the
Joint National Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure: the JNC 7 report. JAMA
2003;289:2560–72.
3. Peters AL, Davidson MB, Schriger DL, Hasselblad V. A clinical
approach for the diagnosis of diabetes mellitus: an analysis using
glycosylated hemoglobin levels. Meta-analysis Research Group on the
Diagnosis of Diabetes Using Glycated Hemoglobin Levels. JAMA
1996;276:1246–52.
4. Rowley KG, Daniel M, O’Dea K. Screening for diabetes in Indigenous
populations using glycated haemoglobin: sensitivity, specificity, post-
test likelihood and risk of disease. Diabet Med 2005;22:833–9.
5. Rehfeld JF, Goetze JP. The posttranslational phase of gene
expression: new possibilities in molecular diagnosis. Curr Mol Med
2003;3:25–38.
6. Goetze JP, Kastrup J, Pedersen F, Rehfeld JF. Quantification of
pro-B-type natriuretic peptide and its products in human plasma by
use of an analysis independent of precursor processing. Clin Chem
2002;48:1035–42.
7. Goetze JP, Mogelvang R, Maage L, et al. Plasma pro-B-type
natriuretic peptide in the general population: screening for left ven-
tricular hypertrophy and systolic dysfunction. Eur Heart J 2006;27:
3004–10.
8. Schiller NB, Shah PM, Crawford M, et al. Recommendations for
quantitation of the left ventricle by two-dimensional echocardiogra-
phy. American Society of Echocardiography Committee on Standards,
Subcommittee on Quantitation of Two-Dimensional Echocardio-
grams. J Am Soc Echocardiogr 1989;2:358–67.
9. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic
assessment of left ventricular hypertrophy: comparison to necropsy
findings. Am J Cardiol 1986;57:450–8.
0. Du Bois D, Du Bois EF. A formula to estimate the approximate
surface if height and weight be known. Arch Intern Med 1916;17:
863–71.1. Devereux RB, Dahlof B, Levy D, Pfeffer MA. Comparison of
enalapril versus nifedipine to decrease left ventricular hypertrophy in
22
2
2
2
2
2
2
1701JACC Vol. 50, No. 17, 2007 Mogelvang et al.
October 23, 2007:1694–701 Discriminating Cardiac From Pulmonary Dyspneasystemic hypertension (the PRESERVE trial). Am J Cardiol 1996;
78:61–5.
2. Tei C, Ling LH, Hodge DO, et al. New index of combined systolic
and diastolic myocardial performance: a simple and reproducible
measure of cardiac function—a study in normals and dilated cardio-
myopathy. J Cardiol 1995;26:357–66.
3. Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides
for community screening for left ventricular hypertrophy and systolic
dysfunction: the Framingham heart study. JAMA 2002;288:1252–9.
4. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR,
Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact
of age and gender. J Am Coll Cardiol 2002;40:976–82.
5. McDonagh TA, Holmer S, Raymond I, Luchner A, Hildebrandt PR,
Dargie HJ. NT-proBNP and the diagnosis of heart failure: a pooled
analysis of three European epidemiological studies. Eur J Heart Fail
2004;6:269–73.6. Costello-Boerrigter LC, Boerrigter G, Redfield MM, et al. Amino-
terminal pro-B-type natriuretic peptide and B-type natriuretic peptide
in the general community: determinants and detection of left ventric-
ular dysfunction. J Am Coll Cardiol 2006;47:345–53.
7. Nielsen OW, McDonagh TA, Robb SD, Dargie HJ. Retrospective
analysis of the cost-effectiveness of using plasma brain natriuretic
peptide in screening for left ventricular systolic dysfunction in the
general population. J Am Coll Cardiol 2003;41:113–20.
8. Heidenreich PA, Gubens MA, Fonarow GC, Konstam MA, Steven-
son LW, Shekelle PG. Cost-effectiveness of screening with B-type
natriuretic peptide to identify patients with reduced left ventricular
ejection fraction. J Am Coll Cardiol 2004;43:1019–26.
9. Siebert U, Januzzi JL Jr., Beinfeld MT, Cameron R, Gazelle GS.
Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to
guide the diagnostic assessment and management of dyspneic patients
in the emergency department. Am J Cardiol 2006;98:800–5.
